Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein

Histology and Histopathology

Volumn 28, Issue 8, 2013, Pages 999-1006

  Brito Armas, J M ^a   Baekelandt, V ^b   Castro Hernandez J R ^a   Gonzalez Hernandez T ^a   Rodriguez M ^a   Fuentes, Rafael Castro ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alpha synuclein (A30P); Lentiviral vectors; Melatonin; Neuroprotection; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; ANTIOXIDANT; COMPLEMENTARY DNA; DOPAMINE; DOPAMINE RECEPTOR; GREEN FLUORESCENT PROTEIN; MELATONIN; NEUROPROTECTIVE AGENT;

ANIMAL; ARTICLE; CHEMISTRY; GENE VECTOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; MALE; METABOLISM; MUTATION; NERVE CELL; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; ANTIOXIDANTS; DNA, COMPLEMENTARY; DOPAMINE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MALE; MELATONIN; MUTATION; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; SUBSTANTIA NIGRA;

EID: 84880405488     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Absi E., Ayala A., Machado A. and Parrado J. (2000). Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain. J. Pineal Res. 29, 40-47.
2. Alexiuk N.A. and Vriend J. (2007). Melatonin: effects on dopaminergic and serotonergic neurons of the caudate nucleus of the striatum of male Syrian hamsters. J. Neural Transm. 114, 549-554.
3. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Hoglinger G.U., Oertel W.H. and Hartmann A. (2008). Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alphasynuclein-deleted mice. Exp. Neurol. 210, 182-193.
4. Baekelandt V., Claeys A., Cherepanov P., De Clercq E., De Strooper B., Nuttin B. and Debyser Z. (2000). DNA-dependent protein kinase is not required for efficient lentivirus integration. J. Virol. 74, 11278-11285.
5. Baekelandt V. Claeys A., Eggermont K., Lauwers E., De Strooper B., Nuttin B. and Debyser Z. (2002). Characterization of lentiviral vectormediated gene transfer in adult mouse brain. Hum. Gene Ther. 13, 841-853.
6. Barlow-Walden L.R., Reiter R.J., Abe M., Pablos M., Menendez-Pelaez A., Chen L.D. and Poeggeler B. (1995). Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int. 26, 497-502.
7. Bensadoun J.C., Déglon N., Tseng J.L., Ridet J.L., Zurn A.D. and Aebischer P. (2000). Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164, 15-24.
8. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V. and Greenamyre J.T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
9. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., Na H.M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R. and Greenamyre J.T. (2006). Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22, 404-420.
10. Blömer U., Naldini L., Kafri T., Trono D., Verma I.M. and Gage F.H. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641-6649.
11. Bonnefont-Rousselot D., Collin F., Jore D. and Gardès-Albert M. (2011). Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J. Pineal Res. 50, 328-335.
12. Bové J., Prou D., Perier C. and Przedborski S. (2005). Toxin-induced models of Parkinson's disease. NeuroRx. 2, 484-494.
13. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. (2009). A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34, 279-290.
14. Capitelli C., Sereniki A., Lima M.M., Reksidler A.B., Tufik S. and Vital M.A. (2008). Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur. J. Pharmacol. 594, 101-108.
15. Chau K.Y., Cooper J.M. and Schapira A.H. (2010). Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem. Int. 57, 525-529.
16. Coyle J.T. and Puttfarcken P. (1993). Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
17. Damier P., Hirsch E.C., Agid Y. and Graybiel A.M. (1999). The substantia nigra of the human brain. II. Patterns of loss of dopaminecontaining neurons in Parkinson's disease. Brain 122, 1437-1448.
18. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R. and Hen R. (2002). Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99, 14524-14529.
19. Déglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira de Almeida L., Zufferey R., Trono D. and Aebischer P. (2000). Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11, 179-190.
20. Ebadi M., Sharma S.K., Ghafourifar P., Brown-Borg H. and El Refaey H. (2005). Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Methods Enzymol. 396, 276-298.
21. Esposito E. and Cuzzocrea S. (2010). Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol. 8, 228-242.
22. Follenzi A., Ailles L.E., Bakovic S., Geuna M. and Naldini L. (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25, 217-222.
23. Gainetdinov R.R., Fumagalli F., Jones S.R. and Caron M.G. (1997). Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322-1325.
24. Galano A., Tan D.X. and Reiter R.J. (2011). Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 51, 1-16.
25. German D.C., Manaye K., Smith W.K., Woodward D.J. and Saper C.B. (1989). Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann. Neurol. 26, 507-514.
26. Gispert S., Del Turco D., Garrett L., Chen A., Bernard D.J., Hamm-Clement J., Korf H.W., Deller T., Braak H., Auburger G. and Nussbaum R.L. (2003). Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 24, 419-429.
27. González-Hernández T., Afonso-Oramas D. and Cruz-Muros I. (2009). Phenotype, compartmental organization and differential vulnerability of nigral dopaminergic neurons. J. Neural Transm. Suppl. 73: 21-37.
28. Gupta Y.K., Gupta M. and Kohli K. (2003). Neuroprotective role of melatonin in oxidative stress vulnerable brain. Indian J. Physiol. Pharmacol. 47, 373-386.
29. Ishido M. (2007). Melatonin inhibits maneb-induced aggregation of asynuclein in rat pheochromocytoma cells. J. Pineal Res. 42, 125-130.
30. Itzhak Y., Martin J.L., Black M.D. and Ali S.F. (1998). Effect of melatonin on methamphetamine-and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization. Neuropharmacology 37, 781-791.
31. Jenner P. (1992). What process causes nigral cell death in Parkinson's disease? Neurol. Clin. 10, 387-403.
32. 2-and Sin-1-induced cell death. Neurobiol. Aging 28, 1709-1717.
33. Junn E. and Mouradian M.M. (2002). Human alpha-synuclein overexpression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320, 146-150.
34. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J. and Björklund A. (2002). Parkinson-like neurodegeneration induced by targeted overexpression of alphasynuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791.
35. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J. and Björklund A. (2003). Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 100, 2884-2889.
36. Klein R.L., King M.A., Hamby M.E. and Meyer E.M. (2002). Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605-612.
37. Klongpanichapak S., Phansuwan-Pujito P., Ebadi M. and Govitrapong P. (2007). Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity. J. Pineal Res. 43, 65-73.
38. Klongpanichapak S., Phansuwan-Pujito P., Ebadi M. and Govitrapong P. (2008). Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells. Neurosci. Lett. 436, 309-313.
39. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L. and Riess O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
40. Lang A.E. and Lozano A.M. (1998). Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053.
41. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B. and Baekelandt V. (2003). Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain. Pathol. 13, 364-372.
42. Lauwers E., Bequé D., Van Laere K., Nuyts J., Bormans G., Mortelmans L., Casteels C., Vercammen L., Bockstael O., Nuttin B., Debyser Z. and Baekelandt V. (2007). Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol. Aging 28, 248-257.
43. Lin A.M., Fang S.F., Chao P.L. and Yang C.H. (2007). Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of alpha-synuclein. J. Pineal Res. 43, 163-171.
44. Lin C.H., Huang J.Y., Ching C.H. and Chuang J.I. (2008). Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J. Pineal Res. 44, 205-213.
45. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N. and Aebischer P. (2002). (alpha)-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99, 10813-10818.
46. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T. and Aebischer P. (2004). Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 101, 17510-17515.
47. Mayer R.A., Kindt M.V. and Heikkila R.E. (1986). Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J. Neurochem. 47, 1073-1079.
48. Moore J.D., West A.B. and Dawson V.L. (2005). Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87.
49. Morgan W.W. and Nelson J.F. (2001). Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTPinduced degeneration of the nigrostriatal pathway. Brain. Res. 921, 115-121.
50. Onyango I.G. (2008). Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem. Res. 33, 589-597.
51. Pablos M.I., Agapito M.T., Gutierrez R., Recio J.M., Reiter R.J., Barlow-Walden L., Acuña-Castroviejo D. and Menendez-Pelaez A. (1995). Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J. Pineal Res. 19, 111-115.
52. Parihar M.S., Parihar A., Fujita M., Hashimoto M. and Ghafourifar P. (2009). Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int. J. Biochem. Cell. Biol. 41, 2015-2024.
53. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J. and Cookson M.R. (2002). Parkin protects against the toxicity associated with mutant alphasynuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007-1019.
54. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I. and Nussbaum R.L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
55. Qian J.J., Cheng Y.B., Yang Y.P., Mao C.J., Qin Z.H., Li K. and Liu C.F. (2008). Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells. Neurosci. Lett. 435, 142-146.
56. Rodriguez C., Mayo J.C., Sainz R.M., Antolín I., Herrera F., Martín V. and Reiter R.J. (2004). Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 36, 1-9.
57. Sae-Ung K., Uéda K., Govitrapong P. and Phansuwan-Pujito P. (2012). Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. J. Pineal Res. 52, 128-137.
58. Schapira A.H. (2006). Etiology of Parkinson's disease. Neurology 66, S10-S23.
59. Schwarting R.K. and Huston J.P. (1996). Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 49, 215-266.
60. Sharma R., McMillan C.R., Tenn C.C. and Niles L.P. (2006). Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1068, 230-236.
61. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R. and Greenamyre J.T. (2002). An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22, 7006-7015.
62. Singhal N.K., Srivastava G., Patel D.K., Jain S.K. and Singh M.P. (2011). Melatonin or silymarin reduces maneb-and paraquatinduced Parkinson's disease phenotype in the mouse. J. Pineal Res. 50, 97-109.
63. Singhal N.K., Srivastava G., Agrawal S., Jain S.K., Singh M.P. (2012). Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol. Neurobiol. 45, 186-199.
64. Smeyne R.J. and Jackson-Lewis V. (2005). The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 134, 57-66.
65. Srinivasan V., Pandi-Perumal S.R., Maestroni G.J., Esquifino A.I., Hardeland R. and Cardinali D.P. (2005). Role of melatonin in neurodegenerative diseases. Neurotox. Res. 7, 293-318.
66. Tapias V., Cannon J.R. and Greenamyre J.T. (2010). Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J. Neurosci. Res. 88, 420-427.
67. Uversky V.N. (2004). Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell. Tissue Res. 318, 225-241.
68. van der Schyf C.J., Castagnoli K., Palmer S., Hazelwood L. and Castagnoli N. Jr (2000). Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox. Res. 1, 261-269.
69. 2in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants. Neurosci. Lett. 342, 124-128.
70. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Gomez Tortosa E., del Ser T., Muñoz D.G. and de Yebenes JG. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.
71. Zennou V., Petit C., Guetard D., Nerhbass U., Montagnier L. and Charneau P. (2000). HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101, 173-185.
72. Zisapel N. (2001). Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell. Mol. Neurobiol. 21, 605-616.
73. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L. and Trono D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880.
74. Zufferey R., Nagy D., Mandel R.J., Naldini L. and Trono D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotech. 15, 871-875.
75. Zufferey R., Donello J.E., Trono D. and Hope T.J. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886-2892.